Hot COVID-19
Home > News > EKF to Highlight Specific Glycemic Control Marker at AACC 2022
Industry Updates New Products Supplier News Upcoming Events business web

EKF to Highlight Specific Glycemic Control Marker at AACC 2022

Hits:213   Date: 7/1/2022
EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637
 

 
The FDA cleared Lucica® Glycated Albumin-L test kit sold exclusively in the U.S. by EKF
For a high res image, please contact sarahp@alto-marketing.com
 
Cardiff, UK – 30th June 2022 EKF Diagnostics, the global in vitro diagnostics company, will be at the 2022 AACC Clinical Lab Expo, Chicago IL, July 26-28, exhibiting its range of laboratory and point-of-care diagnostics products on Booth #3637. This includes the FDA cleared Lucica® Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the U.S. by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate term monitoring of glycemic control in diabetes patients.
 
Lucica® Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analyzers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions and the results are expressed as a ratio (%), minimizing differences in albumin concentrations between patients. Lucica® is also standardized to an established reference material.
 
“The Lucica® Glycated Albumin-L is sold exclusively by EKF Diagnostics in the U.S. and complements our existing diabetes product range, offering its own utility as a specific, intermediate glycemic control marker,” said Shane O’Neill, Global Director of Scientific Affairs, EKF Diagnostics.

Alongside its range of clinical chemistry tests and diagnostics analyzers, also available to view on EKF’s Booth at AACC will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analyzers and associated data on one centralized platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure and effective POC testing using analyzers in many differing locations.
 
EKF Link middleware is an open and flexible solution which can be interfaced to all vendors’ POC analyzers, including EKF’s own portfolio, to enable real-time remote management of data, including patient test results, QC results, operator management and analyzer configuration. The user-friendly software allows POC analyzers to connect to a hospital or laboratory’s IT system, enabling data transfer from the remote analyzers for subsequent processing. This provides hospitals, laboratories and clinicians with the functionality to manage and evaluate their patient and operator data easily and securely.
 
EKF’s portfolio of POC diagnostic devices includes Hemo Control and DiaSpect Tm hemoglobin analyzer ranges, as well as Quo-Lab and Quo-Test HbA1c analyzers. All of these can now be digitally connected from anywhere and securely accessed remotely at any time using EKF Link, thereby enhancing their capabilities.
 
For more information about EKF Diagnostics, please visit https://www.ekfdiagnostics.com/, follow @EKFdiagnostics on twitter, or follow EKF Diagnostics on LinkedIn.
 
This press release is available online at: https://www.ekfdiagnostics.com/specific-glycemic-control-marker-aacc-2022.html
 
About EKF Diagnostics www.ekfdiagnostics.com or www.ekfusa.com
EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, Stanbio Laboratory and DiaSpect brands, specializes in the development, production and worldwide distribution of point-of-care analyzers for use in the detection and management of diabetes and anemia, and also in sports and maternal medicine. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.

Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents, as well as associated analyzers. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.
COVID-19 testing: EKF also sells a range of COVID-19 testing products, including: PrimeStore MTM, an FDA-approved and CE marked sample containment device that allows the safe handling, transportation and analysis of test swabs and samples, which it manufactures under license; and COVID-SeroKlir, a leading ELISA-based antibody test from Kantaro Biosciences that provides a precise quantitative measurement of COVID-19 IgG antibodies.
EKF-diagnostic GmbH
Tel:+49 (0)39 203 7850
E-mail:sales@ekfdiagnostics.com
advertisement